相似文献
1
Genetic polymorphisms of EPHX1, Gsk3beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma.
Leukemia. 2009 Oct;23(10):1913-9. doi: 10.1038/leu.2009.129. Epub 2009 Aug 6.
2
Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma.
Eur J Haematol. 2008 Jun;80(6):490-4. doi: 10.1111/j.1600-0609.2008.01065.x. Epub 2008 Mar 10.
3
CCN1 stimulated the osteoblasts via PTEN/AKT/GSK3β/cyclinD1 signal pathway in Myeloma Bone Disease.
Cancer Med. 2020 Jan;9(2):737-744. doi: 10.1002/cam4.2608. Epub 2019 Nov 26.
4
Dickkopf-related protein 1 expression in bone marrow of multiple myeloma patients: correlation with bone disease and plasma cell malignancy type.
Exp Oncol. 2020 Dec;42(4):285-288. doi: 10.32471/exp-oncology.2312-8852.vol-42-no-4.15289.
5
Dickkopf-1: a suitable target for the management of myeloma bone disease.
Expert Opin Ther Targets. 2009 Jul;13(7):839-48. doi: 10.1517/14728220903025770.
6
Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis.
Oncotarget. 2016 Apr 12;7(15):19589-600. doi: 10.18632/oncotarget.7319.
7
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.
Blood. 2008 Dec 15;112(13):4924-34. doi: 10.1182/blood-2008-02-140434. Epub 2008 Sep 19.
8
Effect of HPSE and HPSE2 SNPs on the Risk of Developing Primary Paraskeletal Multiple Myeloma.
Cells. 2023 Mar 16;12(6):913. doi: 10.3390/cells12060913.
9
C950T and C1181G osteoprotegerin gene polymorphisms in myeloma bone disease.
Hematology. 2014 Jun;19(4):213-6. doi: 10.1179/1607845413Y.0000000114. Epub 2013 Nov 25.
10
Polymorphisms in the heparanase gene in multiple myeloma association with bone morbidity and survival.
Eur J Haematol. 2015 Jan;94(1):60-6. doi: 10.1111/ejh.12401. Epub 2014 Jul 16.
引用本文的文献
1
Genetic Variants in and Are Associated With the Risk of HCV Infection Among Chinese High-Risk Population.
Front Genet. 2021 Mar 25;12:630310. doi: 10.3389/fgene.2021.630310. eCollection 2021.
2
3'-UTR Polymorphisms of Vitamin B-Related Genes Are Associated with Osteoporosis and Osteoporotic Vertebral Compression Fractures (OVCFs) in Postmenopausal Women.
Genes (Basel). 2020 Jun 2;11(6):612. doi: 10.3390/genes11060612.
3
Molecular changes in peripheral blood involving osteoarthritic joint remodelling.
J Oral Rehabil. 2019 Sep;46(9):820-827. doi: 10.1111/joor.12810. Epub 2019 May 11.
4
Pathogenesis of bone disease in multiple myeloma: from bench to bedside.
Blood Cancer J. 2018 Jan 12;8(1):7. doi: 10.1038/s41408-017-0037-4.
5
[Detection of serum DKK1 in multiple myeloma and myeloma bone disease].
Zhonghua Xue Ye Xue Za Zhi. 2015 Aug;36(8):682-5. doi: 10.3760/cma.j.issn.0253-2727.2015.08.011.
6
Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention.
Blood Rev. 2013 Nov;27(6):261-7. doi: 10.1016/j.blre.2013.08.002. Epub 2013 Sep 2.
7
Association of a novel functional promoter variant (rs2075533 C>T) in the apoptosis gene TNFSF8 with risk of lung cancer--a finding from Texas lung cancer genome-wide association study.
Carcinogenesis. 2011 Apr;32(4):507-15. doi: 10.1093/carcin/bgr014. Epub 2011 Feb 2.
本文引用的文献
1
Thalidomide resistance is based on the capacity of the glutathione-dependent antioxidant defense.
Mol Pharm. 2008 Nov-Dec;5(6):1138-44. doi: 10.1021/mp8001232.
2
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.
Blood. 2008 Dec 15;112(13):4924-34. doi: 10.1182/blood-2008-02-140434. Epub 2008 Sep 19.
3
Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival.
BMC Med. 2008 Sep 8;6:26. doi: 10.1186/1741-7015-6-26.
4
WNT signalling in the immune system: WNT is spreading its wings.
Nat Rev Immunol. 2008 Aug;8(8):581-93. doi: 10.1038/nri2360.
5
Wnt signaling: bone's defense against myeloma.
Blood. 2008 Jul 15;112(2):216-7. doi: 10.1182/blood-2008-04-149278.
6
Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth.
Blood. 2008 Jul 15;112(2):374-82. doi: 10.1182/blood-2007-10-120253. Epub 2008 Mar 14.
7
Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma.
Blood. 2008 Jul 1;112(1):196-207. doi: 10.1182/blood-2008-01-132134. Epub 2008 Feb 27.
8
Nuclear GSK-3beta inhibits the canonical Wnt signalling pathway in a beta-catenin phosphorylation-independent manner.
Oncogene. 2008 Jun 5;27(25):3546-55. doi: 10.1038/sj.onc.1211026. Epub 2008 Jan 28.
9
Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo.
Blood. 2008 Mar 1;111(5):2833-42. doi: 10.1182/blood-2007-03-077685. Epub 2007 Dec 19.
10
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.
Blood. 2007 Nov 15;110(10):3744-52. doi: 10.1182/blood-2007-05-093294. Epub 2007 Aug 22.
Zotero 插件